Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
PLoS One ; 18(1): e0279926, 2023.
Article in English | MEDLINE | ID: mdl-36602999

ABSTRACT

BACKGROUND: Timely publication of clinical trials is critical to ensure the dissemination and implementation of high-quality healthcare evidence. This study investigates the publication rate and time to publication of randomized controlled trials (RCTs) registered in the Australian New Zealand Clinical Trials Registry (ANZCTR). MATERIALS AND METHODS: We conducted a cross-sectional study of RCTs registered with the ANZCTR in 2007, 2009, and 2011. Multiple bibliographic databases were searched until October 2021 to identify trial publications. We then calculated publication rates, proportions, and the time to publish calculated from the date of first participation enrolment to publication date. RESULTS: Of 1,970 trial registrations, 541 (27%) remained unpublished 10 to 14 years later, and the proportion of trials published decreased by 7% from 2007 to 2011. The average time to publish was 4.63 years. The prospective trial registration rate for 2007, 2009 and 2011 was 48% (952 trials) and over this time there was an increase of 19% (280 prospective trials). Trials funded by non-Industry organizations were more likely to be published (74%, 1204/1625 trials) than the industry-funded trials (61%, 224/345 trials). Larger trials with at least 1000 participants were published at a rate of 88% (85/97 trials) and on average took 5.4 years to be published. Smaller trials with less than 100 participants were published at a lower rate with 67% (687/1024 trials) published and these trials took 4.31 years on average to publish. CONCLUSIONS: Just over a quarter of all trials on the ANZCTR for 2007, 2009, and 2011 remain unpublished over a decade later. The average time to publication of nearly five years may reflect the larger trials which will have taken longer to recruit participants. Over half of study sample trials were retrospectively registered, but prospective registration improved over time, highlighting the role of mandating trial registration.


Subject(s)
Research Design , Humans , Publication Bias , Cross-Sectional Studies , New Zealand , Australia , Registries , Randomized Controlled Trials as Topic
2.
Addict Biol ; 16(3): 386-92, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21054685

ABSTRACT

Food restriction (FR) augments the behavioral and reinforcing effects of psychomotor stimulants such as cocaine or amphetamine; effects that may be related to the capacity of FR to increase plasma levels of ghrelin (GHR), a 28-amino acid orexigenenic peptide linked to activation of brain dopamine systems. The present study used wild-type (WT) mice or mutant mice sustaining knockout of either GHR [GHR((-/-)) ] or of the growth hormone secretagogue receptor [GHS-R((-/-)) ] and subjected to FR or not to evaluate the role of GHR and GHS-R in cocaine-stimulated locomotion. WT, GHR((-/-)) , and GHS-R((-/-)) mice were either restricted to 60% of baseline caloric intake or allowed to free-feed (FF). Mice were treated with 0, 1.25, 2.5 and 5.0 mg/kg cocaine on separate test days (in random dose order) and forward locomotion was recorded on each drug day for 45 minutes after drug dosing. Food (and water) was available immediately after (but not during) each activity test. For FF mice, there was no interaction between cocaine and GHR status on locomotion. FR-WT mice treated with saline exhibited significant increases in anticipatory locomotion (relative to FF-WT mice), whereas FR-GHS-R((-/-)) mice did not. Cocaine significantly increased locomotion in FR-GHR((-/-)) and FR-GHS-R((-/-)) mice to the levels noted in FR-WT mice. These results suggest that GHS-R activity, but not GHR activity, is required for FR to augment food-associated anticipatory locomotion, but do not support the contention that GHR pathways are required for the capacity of FR to augment the acute effect of cocaine on locomotion.


Subject(s)
Central Nervous System Stimulants/pharmacology , Cocaine/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Food Deprivation/physiology , Ghrelin/genetics , Locomotion/drug effects , Receptors, Ghrelin/genetics , Animals , Anticipation, Psychological/drug effects , Brain/drug effects , Dose-Response Relationship, Drug , Ghrelin/blood , Mice , Mice, Inbred C57BL , Mice, Knockout , Motivation/drug effects
3.
Pharmacol Biochem Behav ; 93(2): 165-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19433104

ABSTRACT

Adult female rats were exposed to lead-free sodium acetate via gavage [0 mg (vehicle control)] or to 16 mg lead as lead acetate for 30 days prior to breeding. Following confirmation of breeding, the female animals continued to be exposed to their respective doses throughout gestation and lactation. When weaned, 16 control and 16 lead-exposed offspring were placed on regular water and food (lead-exposure was discontinued) until postnatal day (PND) 70. At this time, one-half of the control animals and one-half of the lead-treatment animals received intraperitoneal (i.p.) injections of the vehicle (saline) for 10 successive days and the remaining animals in each exposure conditions received daily injections of 1.0 mg/kg (+)-methamphetamine (METH) for 10 days (N=8/group). Locomotion in automated chambers was monitored daily for 45 min post-injection. Subsequently, during dose-effect testing, all animals received consecutive daily i.p. injections of 0, 1.0, 2.0, and then 4.0 mg/kg METH. The results of the experiment showed that both control and lead-exposed animals exhibited heightened locomotor activity (i.e. behavioral sensitization) to the repeated administration of 1.0 mg/kg METH. More importantly, animals developmentally (perinatally) exposed to lead showed more rapid sensitization than did their control counterparts. These data indicate that early lead exposure increases sensitivity to the locomotor-stimulating effects of METH. In contrast, identically exposed lead animals exhibit diminished METH dose-effect responding when tested in an intravenous (i.v.) self-administration paradigm [Rocha A., Valles R., Bratton G.R., Nation J.R. Developmental lead exposure alters methamphetamine self-administration in the male rat: acquisition and reinstatement. Drug Alcohol Depend 2008a;95:23-29, Rocha A., Valles R., Hart N., Bratton G.R., Nation J.R. Developmental lead exposure attenuates methamphetamine dose-effect self-administration performance and progressive ratio responding in the male rat. Pharmacol Biochem Behav 2008b;89:508-514].


Subject(s)
Central Nervous System Stimulants/pharmacology , Lead Poisoning, Nervous System/psychology , Methamphetamine/pharmacology , Amphetamine-Related Disorders/psychology , Animals , Body Weight/drug effects , Central Nervous System Stimulants/pharmacokinetics , Dose-Response Relationship, Drug , Female , Injections, Intraperitoneal , Injections, Intravenous , Lead/blood , Lead/pharmacokinetics , Male , Methamphetamine/pharmacokinetics , Motor Activity/drug effects , Pregnancy , Prenatal Exposure Delayed Effects , Rats , Rats, Sprague-Dawley , Self Administration , Stereotyped Behavior/drug effects
4.
Behav Brain Res ; 197(2): 454-6, 2009 Feb 11.
Article in English | MEDLINE | ID: mdl-18955087

ABSTRACT

Rats undergoing both naloxone-precipitated and spontaneous opioid withdrawal exhibit anxiogenic behaviors in the elevated plus maze (EPM). Recently, we observed an unexpected result, namely mice exhibited increased EPM open-arm time during naloxone-precipitated morphine withdrawal. This was surprising since this behavioral outcome is usually associated with an anxiolytic profile. This study demonstrates that mice exhibit an increase in both EPM open-arm time and % open-arm entries also during spontaneous opioid withdrawal.


Subject(s)
Exploratory Behavior/drug effects , Maze Learning/drug effects , Morphine/pharmacology , Substance Withdrawal Syndrome/physiopathology , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/pharmacology , Animals , Anxiety/physiopathology , Anxiety/psychology , Dose-Response Relationship, Drug , Exploratory Behavior/physiology , Injections, Subcutaneous , Male , Maze Learning/physiology , Mice , Mice, Inbred C57BL , Morphine/administration & dosage , Substance Withdrawal Syndrome/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...